Nasdaq
$24.96▼ 3.96%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $98.3MShares out 3.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.8After-hours26.10.09 07:27SCHEDULE 13G/AOwnership#●●●
vTv Therapeutics Inc.
Integrated Core Strategies (US) LLC and entities affiliated with Millennium Management have entered into a joint filing agreement for the Schedule 13G regarding their beneficial ownership of vTv Therapeutics Inc. Class A common stock. Dated October 7, 2026, this agreement confirms that the filing is made on behalf of all named parties in accordance with Rule 13d-1(k) of the Securities Exchange Act.…more
$24.96-3.96%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:318-KKey event
vTv Therapeutics Inc.
vTv Therapeutics adopted its Third Amended and Restated By-Laws on October 1, 2026. The amendments include revised procedures for nominating directors at stockholder meetings, updated voting standards, and the designation of U.S. federal district courts as the exclusive forum for certain legal actions.…more
$24.96-3.96%vs prev closeView filingShare - 8.6After-hours26.08.07 05:2410-QEarnings
vTv Therapeutics Inc.
vTv Therapeutics는 2026년 상반기 매출 3,684만 달러를 기록하며 전년 동기 대비 흑자 전환한 933만 달러의 영업이익을 달성했습니다. 2026년 6월 30일 기준 현금 및 현금성 자산은 8,664만 달러이며, 연구개발비로 상반기에만 1,775만 달러를 지출했습니다.…more
$24.96-3.96%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Pre-market26.10.12 17:14#●●●#●●●
vTv Therapeutics Advances Oral Cadisegliatin for Type 1 Diabetes
vTv Therapeutics reported that 54% of automated insulin delivery users face hypoglycemia burdens, highlighting the need for its oral candidate, cadisegliatin. The company is accelerating development of this treatment to address the limitations of current insulin delivery methods.…more
$24.96-3.96%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.10Closed26.10.10 21:00
●●●●●●●● ●●●●● ●●●●●●
vTv Therapeutics presented research findings regarding hypoglycemia-related burdens in type 1 diabetes patients at the Breakthrough T1D Congress. This presentation highlights the need for their investigational therapy but does not represent a new clinical milestone or financial result.…more
$24.96-3.96%vs prev close - 10.7After-hours26.10.08 05:02
●●●●●●●● ●●●●● ●●●●●●
vTv Therapeutics announced that its oral Nrf2/Bach1 modulator, HPPD, has received Orphan Drug Designation from the FDA for the treatment of sickle cell disease. This designation provides the company with development incentives and regulatory support as it advances the clinical program.…more
$24.96-3.96%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report